A medication commonly used to treat people with age-related macular degeneration (AMD) may also be beneficial in treating people with a common form of diabetic retinopathy, according to new research.
The Diabetic Retinopathy Clinical Research Network study, published in Ophthalmology online, the journal of the American Academy of Ophthalmology (Academy), shows that ranibizumab (Lucentis) may have multiple benefits.
According to the specialist, treating diabetic macular edema with ranibizumab eye injections, plus laser treatment if needed, results in better vision than laser treatment alone.
Dr Neil Bressler, MD, chief of the retina division at Wilmer Eye Institute, Johns Hopkins University School of Medicine, commented: "The results appear to be applicable to most people who have DME in the centre of the macula with some vision loss, whether the person has Type 1 or Type 2 diabetes, is old or young, or is a woman or a man."
It follows recent research carried out by experts in veterinary ophthalmology from the University of Pennsylvania, who used gene therapy to restore retinal cone function and day vision in two canine models of congenital achromatopsia, also known as total colour blindness.
by Martin Burns